To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Brands and risk of bias lead to inconsistency in trials on glucosamine use for arthritis

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
March 2015

Brands and risk of bias lead to inconsistency in trials on glucosamine use for arthritis

Vol: 4| Issue: 3| Number:63| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1844-55.

Contributing Authors:
P Eriksen EM Bartels RD Altman H Bliddal C Juhl R Christensen

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

This meta-analysis evaluated 25 randomized control trials which assessed the efficacy of glucosamine for pain due to osteoarthritis (OA), when compared to a placebo group. The study included a total of 3,458 patients who were assessed over short- (at least 4 weeks) or long-term (up to 3 years) periods. The purpose of the study was to determine factors which may account for inconsistencies between ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue